Compare PRPL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | ATNM |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 31.7M |
| IPO Year | 2015 | 2013 |
| Metric | PRPL | ATNM |
|---|---|---|
| Price | $8.94 | $0.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $0.65 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 173.0K | 84.8K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | 14.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | $90,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $6.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.28 | $0.81 |
| 52 Week High | $8.50 | $1.81 |
| Indicator | PRPL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 86.98 | 34.03 |
| Support Level | $0.54 | $0.81 |
| Resistance Level | N/A | $1.38 |
| Average True Range (ATR) | 0.62 | 0.03 |
| MACD | 0.40 | -0.00 |
| Stochastic Oscillator | 98.58 | 24.61 |
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.